Latest Biotech News

The FDA granted accelerated approval to AstraZeneca’s oral selective estrogen receptor degrader, camizestrant (Etcamah), for certain patients with HR+/HER2− advanced breast cancer with detected...

Roivant reported new mid-stage success for mosliciguat, an inhaled therapy for serious pulmonary hypertension. In a 16-week Phase 2 study, the company said the drug achieved a statistically...

Bristol Myers Squibb said a pivotal Phase 2 study of its GPRC5D-directed CAR-T cell therapy hit its primary endpoint. The company’s update extends BMS’s efforts to compete for the post-BCMA...

Inhibrx reported an early clinical win for its OX40 agonist, with response signals in head and neck cancer. The company framed the strongest results in a smaller subset of patients with...

Moonwalk Biosciences raised $70 million in a Series B to move its lead adipose-targeted RNAi obesity candidate, MW101, toward first-in-human studies planned for late 2027. The company said...

BrainChild Bio raised $116 million in Series A financing to accelerate development of CAR-T therapies aimed at childhood brain cancers, starting with an investigational program for diffuse...

Fortrea agreed to acquire Worldwide Clinical Trials’ early phase services unit for $45 million, adding a clinical pharmacology bed network and bioanalytical capabilities to Fortrea’s portfolio....

Roche reached a potential $1.53 billion license deal for SIM-0600, a preclinical CD79a/CD19/CD3 trispecific T-cell engager from Simcere Zaiming Pharmaceutical. The agreement reflects Roche’s...

Superluminal Medicines raised an oversubscribed $60 million Series B to advance a selective, biased MC4R agonist for rare genetic and hypothalamic obesity. The company said it plans to initiate...

Roche has signed a licensing deal for SIM-0600, a preclinical CD79a/CD19/CD3-targeting trispecific T-cell engager from Simcere Zaiming Pharmaceutical. The agreement announced the potential value...

GSK moved deeper into antibody-drug conjugates by securing ex-China rights to Hutchmed’s HMPL-A830 under a deal valued at up to $1.295 billion. The preclinical asset pairs an anti-EGFR antibody...

Novartis granted itself a broader pathway into subcutaneous biologic formulations via Alteogen’s ALT-B4 platform. Under option agreements announced after Korean market hours, Alteogen granted...

China’s National Medical Products Administration (NMPA) approved two differentiated therapies aimed at reducing acute and seasonal disease burden. Everest Medicines’ Cardamyst became a...

The FDA approved AstraZeneca’s oral SERD camizestrant (sold as Etcamah) for a subset of patients with HR+/HER2− advanced breast cancer with ESR1 mutations detected during aromatase inhibitor and...

Novartis’ antisense therapy pelacarsen failed to meet clinical endpoints in a Phase 3 outcomes study, dealing another blow to the Lp(a) lowering strategy. The Lp(a)HORIZON study did not reduce the...

Roivant reported that mosliciguat achieved the primary endpoint in a 16-week Phase 2 study of a pulmonary hypertension population, posting a statistically significant 56% reduction in pulmonary...

Moonwalk Biosciences raised $70 million in a Series B round to move its adipose-targeted RNAi obesity candidate MW101 into first-in-human studies planned for late 2027. The company said...

Clean Cells launched next-generation sequencing (NGS)-based viral safety testing for viral matrices, including viral vectors and recombinant preparations, and simultaneously acquired French...

BrainChild Bio secured $116 million in venture financing to support a pivotal development program for pediatric brain tumor CAR-T therapy. The company’s BCB-276 targets B7-H3 (CD276) for diffuse...

The FDA approved AstraZeneca’s oral SERD camizestrant (Etcamah) for a defined subset of patients with HR+/HER2– advanced breast cancer with ESR1 mutations detected during aromatase inhibitor and...